PDB1CD411299

PDB1CD411299 is a protein molecule, based on the type of protein and its primary structure, it is classified as a minor histocompatibility antigen. PDB1CD411299 has started to find applications in areas like tissue and organ transplant rejection, cell therapy, and immunotherapy. This paper will delve into its applications and work prinicple.

Applications

As a minor histocompatibility antigen, PDB1CD411299 is primarily utilized as an immunotherapeutic tool. This therapy entails the utilization of immune-based interventions to fight against diseases like cancer. In particular, PDB1CD411299 has gained traction for its unique ability to induce de novo immune responses to dendritic cell-presented antigen. Besides, the protein holds promise in cell therapy, as its MHC-peptide complexes have been shown to be useful when evaluating donor lymphocyte infusion to treat hematological malignancies.

In addition, PDB1CD411299 has started gaining attention as a means of combating tissue and organ rejection. This application is backed by studies that have proved that the protein molecule plays an integral role in the regulation of lymphocytes, and their associated cellular-mediated immune responses.

Lastly, since MHC-peptide complexes are vital in the prevention of autoimmunity. As such, PDB1CD411299 has been touted as a promising platform for the development of novel autoreactive BLyS/CD40L inhibitors. It is believed that this protein may assist in the improvement of autoimmune protocols.

Working Principle

The working principle of PDB1CD411299 is based on its structural make-up. The protein molecule is composed of two major legs, the N-terminal and the C-terminal. The N-terminal forms the core of the protein, and it consists of four helices of equal size and shape. The helices are held together by an array of conserved hydrophobic and electrostatic interactions. These interactions create a building block that facilitates the formation of a cooperative stabilizing structure.

At the C-terminal end of the protein, the primary structure is mainly composed of alpha-helices. The major actin-binding domain (ABD) of PDB 1CD411299 encompasses the C-terminal alpha-helices. The ABD has the capacity to bind actin and is involved in the regulation of lymphocyte-mediated immune responses. It also plays a significant role in the dendritic cell-mediated antigen presentation.

Besides, the protein has a unique arginine-tyrosine-rich (RT-rich) region, which is involved in T-cell receptor signaling. This region has been proven to hold the probable key to the generation of unique MHC-antigenic peptide complexes. This peptide-MHC complex has been shown to play a critical role in cellular-mediated processes, like altering the antigen presentation and manipulating T-cells.

Conclusion

PDB1CD411299 is a minor histocompatibility antigen protein molecule that has shown potential in the areas of tissue and organ rejection prevention, cell therapy, and immunotherapy. Its unique properties are mostly rooted in its primary structure, with its N-terminal leg comprising of four equally shaped and sized helices, while its C-terminal end having alpha-helices and an arginine-tyrosine-rich (RT-rich) region. These structural components have enabled PDB1CD411299 to aid in the formation of MHC-peptide complexes, which are important in altering the antigen presentation and manipulating T-cells.